Welcome to Multibagg AI
Log in to access personalized features
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Investor Presentation
Q1 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY22
Discovery themes featuring this stockDiscovery themes featuring this stockDiscover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Dr Reddys Laboratories Ltd (DRREDDY) is currently trading at 1,289.50 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Dr. Reddy's Laboratories is a global pharmaceutical company headquartered in Hyderabad, India. It focuses on providing affordable and innovative medicines across major therapeutic areas such as oncology, gastrointestinal, and cardiovascular. The company demonstrated a 4.4% year-on-year revenue growth in Q3FY26, despite facing headwinds from lower sales in certain product lines like Lenalidomide, showcasing its underlying business strength. Dr. Reddy's is making significant advancements in its biotechnology pipeline, with successful biosimilar launches and strategic regulatory approvals in multiple international markets. The firm has embarked on strategic collaborations for innovative drug developments and expanded its generics and biosimilars portfolio across emerging and developed markets. Dr. Reddy's commitment to ESG and sustainability is evidenced by its pledge for science-based net-zero targets by FY2045 and achievements in water security and climate change leadership.
Over the past 52 weeks, Dr Reddys Laboratories Ltd has traded between a low of ₹1,025.90 and a high of ₹1,377.95. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Dr Reddys Laboratories Ltd has a market capitalization of approximately 1,06,903.63. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Dr Reddys Laboratories Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 19.23 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 1,06,903.63 Cr, Dr Reddys Laboratories Ltd is classified as a Mid Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Dr Reddys Laboratories Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Dr Reddys Laboratories Ltd is 19.23. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The most significant announcement is the 'Biopharma Shakti' initiative, a ₹10,000 crore program aimed at making India a global hub for biologics and biosimilars manufacturing, which directly aligns with Dr. Reddy's strategic growth areas.
| Symbol | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
1348.00 | 1,08,978 Cr | 22.90 | 3.31 | 1.19 | 16.53 | 21.05 | 11.32 | |
1283.00 | 1,06,904 Cr | 19.23 | 2.97 | 0.62 | 16.03 | 18.66 | 10.16 | |
2223.80 | 1,01,749 Cr | 20.43 | 5.18 | 0.54 | 22.03 | 21.92 | 13.94 | |
910.05 | 91,572 Cr | 17.91 | 3.62 | 1.21 | 19.44 | 19.08 | 10.52 | |
2072.00 | 85,665 Cr | 46.03 | 5.60 | 0.00 | 11.45 | 12.34 | 6.26 | |
1171.20 | 67,358 Cr | 19.26 | 1.92 | 0.00 | 9.77 | 12.69 | 6.63 | |
5463.60 | 65,331 Cr | 27.20 | 4.90 | 0.82 | 17.69 | 18.13 | 11.95 |
Trademark Acquisition
Dr. Reddy's entered a definitive agreement to acquire the Progynova and Cyclo‑Progynova trademarks and related Indian assets from Mercury Pharma Group for USD 32.15 million to enter the HRT segment and strengthen its gynaecology portfolio.
Brand/Asset Acquisition
Dr. Reddy's has entered a definitive agreement to acquire the Indian trademarks and related assets for Progynova® and Cyclo‑Progynova® from Mercury Pharma Group Ltd. for USD 32.15 million to enter the HRT segment and strengthen its gynaecology portfolio.
Bearish
6
Neutral
3
Bullish
5
Bearish
6
Neutral
3
Bullish
37
Bearish
0
Neutral
0
Bullish
32
Dr. Reddy's Laboratories is a global pharmaceutical company headquartered in Hyderabad, India. It focuses on providing affordable and innovative medicines across major therapeutic areas such as oncology, gastrointestinal, and cardiovascular.
The company demonstrated a 4.4% year-on-year revenue growth in Q3FY26, despite facing headwinds from lower sales in certain product lines like Lenalidomide, showcasing its underlying business strength.
Dr. Reddy's is making significant advancements in its biotechnology pipeline, with successful biosimilar launches and strategic regulatory approvals in multiple international markets.
The firm has embarked on strategic collaborations for innovative drug developments and expanded its generics and biosimilars portfolio across emerging and developed markets.
Dr. Reddy's commitment to ESG and sustainability is evidenced by its pledge for science-based net-zero targets by FY2045 and achievements in water security and climate change leadership.
Pharmaceuticals
Pharmaceuticals - Indian - Bulk Drugs & Formln Lrg
1,06,904 Cr
Low Risk
19.2
26.5
—
3.0
1,377.95
1,025.90
Sales CAGR
Profit CAGR
ROE
ROCE
